Establishment Labs (NASDAQ:ESTA) Announces Quarterly Earnings Results

Establishment Labs (NASDAQ:ESTA) released its earnings results on Wednesday. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.07, Briefing.com reports. The company had revenue of $37.17 million for the quarter, compared to analysts’ expectations of $35.61 million. Establishment Labs had a negative return on equity of 357.81% and a negative net margin of 47.53%. The business’s revenue for the quarter was down 20.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.48) EPS. Establishment Labs updated its FY 2024 guidance to EPS.

Establishment Labs Price Performance

Shares of ESTA stock traded up $5.69 during trading on Thursday, hitting $56.94. The company had a trading volume of 386,953 shares, compared to its average volume of 405,870. Establishment Labs has a 52 week low of $16.96 and a 52 week high of $73.00. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -18.57 and a beta of 1.23. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 10.26. The stock’s 50-day moving average is $50.27 and its two-hundred day moving average is $37.38.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. JPMorgan Chase & Co. increased their target price on shares of Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. Mizuho lifted their price objective on Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, April 1st. Stephens reiterated an “overweight” rating and set a $47.00 target price on shares of Establishment Labs in a research report on Thursday, January 11th. Finally, Citigroup raised their price objective on shares of Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Establishment Labs has an average rating of “Buy” and a consensus price target of $55.00.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.